Gobel B et al, eds. Cancer prevention, screening, and early detection. In: Advanced Oncology Nursing Certification: Review & Resource Manual. 2nd ed. Pittsburgh, PA: Oncology Nursing Society; 2016. Abstract

Gobel B et al, eds. Genetic risk. In: Advanced Oncology Nursing Certification: Review & Resource Manual. 2nd ed. Pittsburgh, PA: Oncology Nursing Society; 2016. Abstract

Goldman JW et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): Updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2021;22(1):51-65. Abstract

Leal JFM et al. PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity. Br J Pharmacol 2010;161(5):1099-110. Abstract

Liu SV et al. Impower133: Primary PFS, OS, and safety in Ph1/3 study of 1L atezolizumab + carboplatin + etoposide in extensive-stage SCLC. WCLC 2018;Abstract PL02.07.

Liu SV et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (Impower133). J Clin Oncol 2021;39(6):619-30. Abstract

Paz-Ares LG et al. Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the phase III CASPIAN study. ESMO 2021;Abstract LBA61.

Paz-Ares LG et al. Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study. ASCO 2020;Abstract 9002.

Paz-Ares et al. Lurbinectedin/doxorubicin versus CAV or topotecan in relapsed SCLC patients: Phase III randomized ATLANTIS trial. WCLC 2021;Abstract PL02.03.

Santamaría Nuñez G et al. Lurbinectedin specifically triggers the degradation of phosphorylated RNA polymerase II and the formation of DNA breaks in cancer cells. Mol Cancer Ther 2016;15(10):2399-412. Abstract

Trigo J et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: A single-arm, open-label, phase 2 basket trial. Lancet Oncol 2020;21(5):645-54. Abstract

Weiss J et al. Effects of trilaciclib on chemotherapy-induced myelosuppression and patient-reported outcomes in patients with extensive-stage small cell lung cancer: Pooled results from the three Phase II randomized, double-blind, placebo-controlled studies. Clin Lung Cancer 2021;22(5):449-60. Abstract